ANCA相关性血管炎中炎症性眼病的临床特征:回顾性队列研究
该回顾性队列研究纳入2003至2013年Mayo Clinic确诊的1171例ANCA相关性血管炎(AAV)患者,其中183例(约16%)合并炎症性眼病(IOD)。最常见表现为巩膜炎、表层巩膜炎和眶内炎症,多数对糖皮质激素和免疫抑制治疗反应良好,但IOD复发常见。
要点
- AAV患者中约16%合并炎症性眼病,巩膜炎、表层巩膜炎和眶内炎症最常见。
- 96%的IOD患者接受口服糖皮质激素治疗,环磷酰胺和利妥昔单抗是最常用免疫抑制剂。
- IOD临床缓解率达91%,但复发率为23%,眶内炎症患者中52%需治疗性手术干预。
核心结论
- 炎症性眼病是ANCA相关性血管炎的常见表现,约见于16%的患者。
- 巩膜炎、表层巩膜炎和眶内炎症是最常见的IOD亚型。
- 多数患者对糖皮质激素和免疫抑制治疗反应良好,但IOD复发常见。
研究设计与样本
- 回顾性队列研究,复习2003至2013年Mayo Clinic潜在AAV病例记录。
- 采用2012年Chapel Hill共识会议描述标准确认AAV诊断。
- 共确认1171例AAV,其中183例合并IOD(平均年龄49.0岁,51%女性,95%白人)。
主要发现
- IOD最常见表现为眼充血(57%),其次为眼痛(46%)和视力下降(18%)。
- IOD亚型:巩膜炎22%、表层巩膜炎21%、眶内炎症18%、泪管狭窄10%、葡萄膜炎9%。
- 96%的IOD患者使用口服糖皮质激素治疗,环磷酰胺和利妥昔单抗使用率分别为54%和36%。
- 眶内炎症患者中52%接受治疗性手术干预。
- IOD临床缓解率91%,复发率23%;仅6例患者出现显著视力下降。
关键数值与推荐
- AAV诊断采用2012年Chapel Hill共识会议描述标准。
- IOD临床缓解定义为91%的患者达到缓解,复发见于23%的患者。
- 显著视力下降仅见于6例患者。
临床怎么用
- 对AAV患者应警惕炎症性眼病,约16%合并IOD,需及早识别。
- 巩膜炎、表层巩膜炎和眶内炎症是最常见亚型,眶内炎症常需手术干预。
- 糖皮质激素联合免疫抑制剂(环磷酰胺或利妥昔单抗)是主要治疗,但需监测复发。
局限性
- 回顾性研究设计,可能存在选择和信息偏倚。
- 研究基于Mayo Clinic单中心数据,外推性有限。
- 原文未报告IOD与AAV亚型或ANCA特异性的详细关联分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the clinical correlates and outcome of inflammatory ocular disease (IOD) among patients with ANCA-associated vasculitides (AAV). METHODS: Medical records of potential cases of AAV seen at Mayo Clinic from 2003 to 2013, inclusive, were reviewed to identify confirmed cases meeting the diagnosis of AAV using the Chapel Hill Consensus Conference 2012 descriptors. Records of confirmed cases of AAV were then further reviewed for IOD, and clinical characteristics, treatment and outcomes abstracted. RESULTS: A total of 1171 confirmed cases of AAV were identified of which 183 patients (mean age 49.0 years; 51% female; 95% Caucasian) had IOD. The most common manifestation of IOD was injection of the eye (57%) followed by eye pain (46%) and visual acuity loss (18%). Scleritis was the most common type of IOD (22%) followed by episcleritis (21%), orbital inflammation (18%), lacrimal duct stenosis (10%) and uveitis (9%). Oral glucocorticoids were used to treat IOD in the majority of patients (96%). CYC and rituximab were the most frequently used immunosuppressive agents (54 and 36%, respectively). Of those with orbital inflammation, 52% underwent therapeutic surgical intervention. Clinical remission of IOD was achieved in 91% of patients but relapses were seen in 23%. Significant visual acuity loss was observed in only six patients. CONCLUSION: IOD is a common manifestation of AAV and seen in about 16% of patients with AAV. Scleritis, episcleritis and orbital inflammation are the most common subtypes. Most patients respond well to glucocorticoids and immunosuppression, but relapse of IOD is common.
引用
- Ungprasert P, Crowson CS, Cartin-Ceba R, et al. Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study. Rheumatology (Oxford). 2017. PMID: 28957561. doi:10.1093/rheumatology/kex261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。